首页> 外文期刊>Psychopharmacology >Evaluating non-medical prescription opioid demand using commodity purchase tasks: test-retest reliability and incremental validity
【24h】

Evaluating non-medical prescription opioid demand using commodity purchase tasks: test-retest reliability and incremental validity

机译:使用商品购买任务评估非医疗处方表阿片类药物需求:测试 - 重新测试可靠性和增量有效性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Rationale Non-medical prescription opioid use and opioid use disorder (OUD) present a significant public health concern. Identifying behavioral mechanisms underlying OUD will assist in developing improved prevention and intervention approaches. Behavioral economic demand has been extensively evaluated as a measure of reinforcer valuation for alcohol and cigarettes, whereas prescription opioids have received comparatively little attention. Objectives Utilize a purchase task procedure to measure the incremental validity and test-retest reliability of opioid demand. Methods Individuals reporting past year non-medical prescription opioid use were recruited using the crowdsourcing platform Amazon Mechanical Turk (mTurk). Participants completed an opioid purchase task as well as measures of cannabis demand, delay discounting, and self-reported pain. A 1-month follow-up was used to evaluate test-retest reliability. Results More intense and inelastic opioid demand was associated with OUD and more intense cannabis demand was associated with cannabis use disorder. Multivariable models indicated that higher opioid intensity and steeper opioid delay discounting rates each significantly and uniquely predicted OUD. Increased opioid demand intensity, but not elasticity, was associated with higher self-reported pain, and no relationship was observed with perceived pain relief from opioids. Opioid demand showed acceptable-to-good test-retest reliability (e.g., intensity r(xx) = .75; elasticity r(xx) = .63). Temporal reliability was lower for cannabis demand (e.g., intensity r(xx) = .53; elasticity r(xx) = .58) and discounting rates (r(xx) = .42-.61). Conclusions Opioid demand was incrementally valid and test-retest reliable as measured by purchase tasks. These findings support behavioral economic demand as a clinically useful measure of drug valuation that is sensitive to individual difference variables.
机译:理由非医疗处方阿片类药物和阿片类药物使用障碍(Oud)提出了重大的公共卫生问题。识别ouding oud的行为机制将有助于制定改进的预防和干预方法。行为经济需求已被广泛评估为酒精和香烟的增强剂估值的衡量标准,而处方阿片类药物的关注相对较少。目标利用购买任务程序来测量表述需求的增量有效性和测试 - 重度可靠性。方法使用众包平台亚马逊机械土库(MTURK)招聘了报告过去年度非医疗处方阿片类药物的个体。与会者完成了阿片类药物购买任务以及大麻需求的措施,延迟折扣和自我报告的疼痛。使用1个月的随访,用于评估测试 - 保持性可靠性。结果更强烈和不弹性的表述需求与Oud相关,并且更强烈的大麻需求与大麻使用障碍有关。多变量模型表明,较高的阿片类强度和陡峭的阿片类药物延迟折扣率,每个延迟率和唯一的预测oud。增加阿片类药物需求强度,但不是弹性,与较高的自我报告的疼痛有关,并且没有观察到来自阿片类药物的疼痛缓解。阿片类药物的需求显示出可接受的至良好的测试 - 保持性可靠性(例如,强度R(XX)= .75;弹性R(XX)= .63)。对于大麻需求(例如,强度R(XX)= .53;弹性R(XX)= .58)和折扣率(r(xx)= .42-.61)的时间可靠性较低。结论ApioID需求逐步有效,并按购买任务衡量的可靠性可靠。这些调查结果支持行为经济需求作为对单个差分变量敏感的药物估值的临床有用的衡量标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号